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Abstract
Background: The ST2/IL-33 pathway has been related to ulcerative colitis (UC), and soluble ST2 (sST2), to disease
severity. We tested the potential usefulness of sST2 as a predictive marker of treatment response and patients’
outcome.
Methods: Twenty-six patients with active UC were prospectively recruited and grouped according to an endoscopic
score and therapy response. Colonoscopic biopsies were collected at baseline and 6 months or when patients showed
clinical activity. The protocol was reinitiated in patients requiring rescue therapy. Blood and stool were collected at
baseline, 1, 3, 6 and 12 months. Serum and mucosal ST2, and fecal calprotectin (FC) content were determined by ELISA
and correlated to Mayo clinical and endoscopic subscore. Intestinal ST2 was evaluated by immunofluorescence.
Wilcoxon signed rank test and Spearman correlations (Rs) were applied (p <0.05).
Results: Follow-up was completed in 24 patients. sST2 levels (median and range) varied from 173.5 [136.6–274.0] to 86.
5 [54.6–133.2] in responders (p < 0.05), and 336.3 [211.0–403.2] to 385.3 pg/mL [283.4–517.3] in non-responders at
baseline and 6 months, respectively. sST2 levels correlated with Mayo clinical and endoscopic subscore, mucosal ST2
and FC (Rs = 0.57, 0.66, 0.74 and 0.42, respectively; p < 0.0001) and showed a trend similar to that of FC in responders.
Non-responders revealed an increased ST2 content, restricted to the lamina propria’s cellular infiltrate.
Conclusions: Consecutive sST2 measurement to follow changes in inflammatory activity of UC patients who respond
or not to treatment identifies sST2, like FC, as a useful biomarker in predicting clinical outcome of UC patients.
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Background
The two main subtypes of inflammatory bowel diseases
(IBD), Crohn’s disease (CD) and ulcerative colitis (UC),
are characterized by episodes of inflammatory activity
and remission. To explain the multifactorial and poly-
genic nature of IBD, a scenario of chronic and uncon-
trolled activation of the mucosal immune response in
genetically susceptible individuals, exacerbated by envir-
onmental factors, has been proposed [1].
Treatment of IBD seeks to induce and maintain remis-
sion, as well as reduce inflammation, promote mucosal
healing and prevent complications [2], such that the
choice of optimal therapy is crucial for patient recovery.
In most cases, the disease can be controlled with con-
ventional treatment, such as 5-aminosalicylate (5-ASA)
derivatives, corticosteroids and immunosuppressants.
However, patients who do not respond to these treat-
ments eventually require biological therapy and, as a
final alternative, colectomy. While clinical tools, such as
assessment of symptoms/signs, performance of labora-
tory markers [3], colonoscopy/sigmoidoscopy and im-
aging modalities may allow monitoring the response to a
selected therapy, only endoscopic studies definitively
diagnose IBD and evaluate its activity through detection
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of intestinal lesions [4]; unfortunately this procedure is
invasive and costly. Determination of disease activity re-
mains challenging, with most clinical scores correlating
poorly with the inflammatory state [4, 5]. Treatment of
IBD patients has recently shifted from controlling symp-
toms to promoting endoscopic mucosal healing or deep
remission [6], features that are now major endpoints in
clinical trials and are highly efficient in predicting long-
term remission and preventing hospitalization and
surgery.
Treatment promoting mucosal healing can slow the
progression of the disease [6]. In this context, laboratory
biomarkers have gained importance in evaluating and
predicting the response to therapy [7, 8]. Recently, key
molecules that regulate mucosal immunity and IBD
pathogenesis, including those in the IL-33/ST2 signaling
pathway, have emerged as suitable biomarkers in inflam-
matory conditions such as IBD [9, 10]. In humans,
IL1RL1 expression is regulated by distal and proximal
promoters that govern expression of the ST2
membrane-anchored receptor (ST2L) and a soluble iso-
form (sST2) generated by alternative splicing. sST2 is
identical to the ST2L extracellular domain and is a
decoy receptor for IL33 [11]. The IL-33/ST2 axis has
been implicated in numerous other diseases, such as
asthma, rheumatoid arthritis, cancer and Alzheimer’s
disease [9, 12–14].
We previously proposed the sST2 variant as a poten-
tial severity biomarker, mainly in UC patients, that might
allow differentiation between active and inactive disease
[15]. However, sST2 behavior during the clinical course
and response to therapy has not been explored. Here, we
examined whether changes in serum ST2 levels can pre-
dict response to treatment, clinical activity and disease




In this observational study, we prospectively included
patients with relapsed IBD from Clínica Las Condes.
The diagnosis of UC was established according to inter-
national guidelines including clinical, endoscopic, histo-
logic and radiologic criteria [16, 17]. Patients were
assessed at a minimum of 3-month intervals or upon re-
lapse. The follow-up period was 12 months in patients
showing no relapse and in patients showing activity
flares and requiring rescue therapy (Fig. 1a). All relapses
were sufficiently severe to warrant a change in
treatment.
Patients were excluded from the study based on the
following criteria: incomplete ileo-colonoscopy (ileum
not intubated), non-classifiable IBD or coexisting cardio-
pulmonary, renal, hepatic, celiac disease, neurologic,
psychiatric, severe allergy and rheumatologic disease, a
history of HIV, previous ileostomy or colostomy, and
conditions associated with elevated FC levels [18, 19],
i.e., non-steroidal anti-inflammatory or anti-coagulant
drug use in the 6 months preceding enrollment, a his-
tory of erosive/ulcerative upper gastrointestinal disease
within 2 months prior to the study or gastrointestinal in-
fection within 4 weeks prior to the study and those pa-
tients treated with biological therapy. The source data
was encrypted and the data extracted were anonymous.
This study was performed in accordance with the Dec-
laration of Helsinki and the protocol was approved by
Clinica Las Condes Review Board of the Universidad de
Chile, Chile. All patients gave written informed consent.
Clinical activity index
During clinic visits, general well-being, stool frequency,
stool consistency and presence or absence of abdominal
pain, tenderness, tenesmus, rectal bleeding, and mucus
in stool were recorded. Clinical activity indices were
scored according to data available in patient records
using the Mayo clinical subscore at baseline and at 1, 3,
6 and 12 months or, in the case of flare, during the
follow-up period. Three clinical variables were graded:
frequency of evacuation, amount of blood in stool, and
the physician’s global assessment. A Mayo clinical sub-
score of 0 was defined as remission, 1–3 as mildly active
disease, 4–6 as moderately active disease, and ≥7 as se-
verely active disease [20].
All clinical decisions were made independently of ST2
protein level measurements, since detections were per-
formed only after follow-up was completed.
Endoscopic assessment of disease activity
Endoscopic findings were scored according to the Mayo
endoscopic subscore, graded as normal (0), mild (1),
moderate (2), or severe (3) disease activity. Subscore 0–1
was defined as remission and subscore ≥2 as active dis-
ease [21]. Colonoscopic biopsies were collected at base-
line (colonoscopy 1) and at 6 months or if patients
showed clinical signs of activity (colonoscopy 2). Patients
who required rescue therapy reinitiated the protocol.
Endoscopic re-evaluation in patients receiving conven-
tional or biological therapy was conducted at 6 months
or 14 weeks, respectively, or when flares were evident.
Disease activity was assessed based on the results of
clinical activity scoring but blinded to quantitative FC
values. Clinical response was defined as a decrease from
baseline in the total Mayo score by at least three points
and at least 30 %, with an accompanying decrease in the
subscore for rectal bleeding of at least one point or an
absolute subscore for rectal bleeding of 0 or 1. Mucosal
healing was defined as an absolute subscore for endos-
copy of 0 or 1. Patients who had a clinical response at
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each time during the follow-up were considered to have
a sustained clinical response [22].
Medical treatment
Patients enrolled in the study were treated with conven-
tional therapy, such as 5-ASA derivatives, corticosteroids
or immunomodulators (azathioprine/6-mercaptopurine),
depending on disease severity. The decision to change
medical treatment was based on clinical and/or endo-
scopic evaluation. Physicians were blinded to results of
individual quantitative FC values at the time of the
patient’s visit. Rescue therapy was defined as: (a) an in-
creased dose of any previously administered medication;
or (b) a change in medication to corticosteroids, immu-
nosuppressants (azathioprine/6-mercaptopurine) or anti-
TNF (infliximab/adalimumab). Information about the
drug, dose and duration of treatment was obtained from
the medical history.
Measurement of ST2 and IL-33
A blood sample was collected at baseline and at 1, 3, 6
and 12 months of follow-up on the day of colonoscopy
or physical examination (Fig. 1a). Serum and intestinal
ST2 concentrations, as well as serum IL-33 content,
were measured using an enzyme-linked immunosorbent
assay (ELISA) kit for human ST2 or IL-33 (DuoSet,
Fig. 1 Study selection and flow-chart of UC patients’ 1-year follow-up. a Follow-up scheme protocol performed in active UC patients receiving
conventional therapy (baseline). Responder UC patients completed the entire follow-up period. Non-responder patients re-started the follow-up
with biological therapy and were examined at 1 month, 14 weeks, 6 and 12 months. Clinical subscore, FC and serum sST2 were evaluated at 1, 3,
6 and 12 months. Endoscopic subscore and intestinal ST2 were determined at baseline, 14 weeks (w) and 6 months. b Flow-chart of patients
enrolled in the follow-up
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R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions and expressed as pg/mL.
Blood samples were centrifuged and serum was stored at
−80 °C. For ST2 and IL-33 detection, serum samples
were thawed and treated with protein A/G PLUS-
agarose (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Protein extracts of colonic mucosa were obtained
from each biopsy by homogenization using a lysis buffer
supplemented with a protease inhibitor cocktail
(Complete Mini, Roche Diagnostics, Basel, Switzerland)
and subsequently disrupted by sonication. Levels of total
intestinal ST2 were adjusted to total protein concentra-
tion determined by Bradford protein assay (Bio-Rad).
The ST2 detection assay is stable over time, with a de-
tection limit of 20 pg/mL, while the IL-33 detection
assay is less stable over time, with a detection limit of
23.40 pg/mL, according to the manufacturer’s informa-
tion. All samples were analyzed in duplicate; within-run
and total coefficients of variation were ≤2.5 and ≤4.0 %,
respectively.
Using the cut-off for sST2 previously estimated at
<74.87 pg/mL [15], we determined the specificity, sensi-
tivity, positive predictive value and negative predictive
value for our patient cohort.
Fecal calprotectin measurement
A fecal sample was collected at baseline and at, 1, 3, 6
and 12 months of follow-up (Fig. 1a) 24 h before colon-
oscopy or physical examination. Feces (50 mg) was re-
suspended in 500 μL of extraction buffer, spun for
10 min and centrifuged for 10 min at 10,000 rpm. The
supernatant was immediately processed for rapid semi-
quantitative test (Calprotectin 50 + 200, CerTest Biotec
S.L. Spain) or stored at −80 °C for subsequent quantifi-
cation using a standard ELISA with a solid bound spe-
cific antibody and biotinylated tracer antibody according
to the manufacturer’s instructions (Hycult Biotech,
HK325-02, The Netherlands). Detection levels were 1.6–
100 ng/mL, corresponding to 40–2500 μg calprotectin/g
of feces, adjusted for the dilution factor.
Clinical decisions to change therapy were based on
semi-quantitative analysis of calprotectin and independ-
ent of quantitative ELISA after completed follow-up.
Endpoints
The correlation of ST2 and FC measurements with clin-
ical and endoscopic activity scoring was the primary
endpoint of the study. Complete response (remission)
was defined as the absence of symptoms, normal stool
frequency, absence of rectal bleeding, general wellness
based on the patient’s functional assessment score and
endoscopy findings of subscore 0–1 [21]. Biological
remission also implies healing of mucosa and
normalization of inflammation biomarkers, such as
serum sST2 (<74.87 pg/mL) [15] and FC, according
to the cut-off obtained from our patient cohort.
Mucosal ST2 detection by immunofluorescence
Intestinal mucosa biopsies were reviewed by a patholo-
gist experienced in IBD who was blinded to any clinical
information about the patients. Mucosal tissue sections
comprised the most inflamed segment according to
chronic inflammatory infiltrate.
Biopsies were obtained at baseline and at 6 months or
at baseline and 14 weeks in patients treated with con-
ventional treatment and those rescued with biological
therapy, respectively. Total ST2 content was detected in
2 % PFA-fixed, paraffin-embedded UC patient biopsies
cut into 4-μm sections and subjected to immunofluores-
cence analysis. Non-specific binding was blocked and
samples were incubated with a mouse monoclonal anti-
body against human ST2 (MAB523, R&D Systems)
followed by an Alexa 546-tagged secondary goat anti-
body against mouse IgG (Invitrogen/Life Technologies,
Carlsbad, CA, USA) to detect ST2. Cell nuclei were
stained using Hoechst 33342 (Thermo/Life Technolo-
gies, Carlsbad, CA, USA). Images were captured using
an Olympus confocal laser scanning biological micro-
scope FV10i (Olympus America Inc., Melville, NY, USA)
and processed using ImageJ (NIH, Bethesda, MD USA).
Negative controls were prepared under conditions iden-
tical to those described above using an isotype control.
Statistical analyses
Data were analyzed using GraphPad Prism5 (La Jolla,
CA USA). Results of parametric numerical data are
given as mean ± standard deviation (SD) and, in non-
parametric distributions, as median and interquartile
range (IQR). Serial assessments of change from baseline
in serum ST2 and FC levels were compared using the
Wilcoxon signed rank test. Differences and significance
during follow-up times were analyzed by multiple com-
parisons using the non-parametric Kruskal-Wallis test
with Dunn’s multiple comparison post-test. Correlations
between sST2 levels and total intestinal ST2, FC, and
clinical and activity score were analyzed using Spear-
man’s rank correlation coefficient (r). For each test,
differences were considered significant at p ≤ 0.05.
Results
Serum ST2 and clinical characteristics of patients
Table 1 summarizes the clinical characteristics of 26 pa-
tients included in the protocol, while Fig. 1a shows the
flow-chart of the 1-year follow-up enrollment and sam-
pling overview at each stage of the patient’s monitoring.
Baseline ileo-colonoscopy data were available for 26
UC patients. During the study, 24 patients finished the
protocol, six of whom showed disease reactivation, once
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in four patients after 6 months and twice in two patients
before and after 6 months, for a total of eight reactiva-
tion episodes in six presumed non-responder patients.
Overall, 18 patients responded to treatment and six pa-
tients did not (Fig. 1b). Baseline sST2 levels were
189.5 pg/mL [154.1–286.9]; at 1, 3, 6 and 12 months,
with levels of 87.3 [70.1–142.2], 73.25 [55.1–145.1], 95.8
[55.7–134.9] and 78.0 [59.9–99.8] pg/mL, respectively
(Fig. 2a). When patients were grouped according to
treatment response, baseline levels were 173.5 [136.6–
274.0], whereas sST2 levels at 6 months decreased to
86.5 [54.6–133.2] pg/mL in responders and increased in
the eight reactivation episodes from 336.3 [211.0–403.2]
to 385.3 [283.4–517.3] pg/mL in the six non-responders
(Fig. 2b). No significant differences between therapy re-
sponder and non-responder patients were found in base-
line sST2 values (p = 0.1057). Quantitation of FC at
baseline, at 1, 3, 6 and 12 months revealed levels of
147.0 [102.1–210.2], 107.1 [54.2–161.3], 119.5 [57.7–
144.5], 85.4 [63.0–96.7] and 74.7 [48.9–1076.0] μg/g
feces, respectively (Fig. 2c). According to treatment,
baseline FC levels of 141.4 [92.9–204.6] decreased to
82.8 [59.2–97.8] μg/g feces in responders and from
243.9 [175.1–297.9] to 152.0 [100.1–200.8] μg/g feces in
non-responders at 6 months (Fig. 2d). sST2 levels in all
follow-up times correlated with the Mayo clinical sub-
score (Rs = 0.57, p < 0.0001); at baseline and 6 months,
levels correlated with Mayo endoscopic subscores (Rs =
0.66, p < 0.0001) and total ST2 content in mucosa (Rs =
0.74, p < 0.0001) (Fig. 2e). Patients in biological remis-
sion showed normalization of the inflammation bio-
marker sST2, with values below the cut-off of 74.87 pg/
mL [15]. Considering this cut-off value of sST2, the spe-
cificity, sensitivity, PPV and NPV were 0.44, 0.95, 0.62,
and 0.90, respectively.
When patients were grouped according to treatment
response, IL-33 baseline levels were 199.8 [51.92–
372.20], decreasing at 6 months to 141.2 [44.00–352.90]
pg/mL in responders, and decreasing from 629.0 [49.56–
716.8] to 217.9 [50.39–647.5] pg/mL in the reactivation
episodes, both without significant differences (p > 0.05)
(Additional file 1: Figure S1).
Relationship of ST2 to the FC biomarker
Analysis showed that sST2-circulating levels directly
correlated with those of FC (Rs = 0.42, p < 0.0001) in all
patients (Fig. 3a). Intestinal total ST2 levels in mucosa
also correlated with those of FC, although the associ-
ation was less significant statistically (Rs = 0.35, p =
0.044) (Fig. 3b).
sST2 response to biological therapy
In our cohort, six patients were rescued with biological
therapy. Immediately after infliximab infusions, sST2
levels were markedly increased, but protein content dur-
ing the induction period gradually declined between
weeks 3 and 24 of monitoring, reaching levels similar to
those in patients responding to treatment (p < 0.01,
Fig. 4a). A similar trend was observed for FC levels,
indicating that fecal biomarker content also decreases
gradually as a function of type and response to therapy
(p < 0.05; Fig. 4b).
Intestinal total ST2 immunoreactivity
Because intestinal ST2 levels were highly correlated with
sST2 concentrations (Fig. 2e), we tested whether the
total mucosal ST2 content, as the source of ST2 in the
periphery, might be related to healing and deep remission
in responder patients. Mucosal ST2 immunoreactivity de-
tected by immunofluorescence may allow identification of
membrane-anchored ST2 and the soluble variant re-
stricted to the intracellular compartment. In responder
patients, total ST2 immunoreactivity was maintained in
the cellular infiltrate of the lamina propria at 6 months of
follow-up, whereas patients showing reactivation revealed
increased total ST2 in inflamed mucosa but also confined
to the cellular infiltrate (Fig. 5a,b). No immunoreactivity
Table 1 Clinical and demographic data of ulcerative colitis patients
Number
Number of patients 26
Number of patients dropped out 2
Female/male 16/10
Median [range] age at entry 34.5 [30.0–52.5]
Duration of UC, years (median, range) 4.0 [1.3–11.8]






Mild/ Moderate/ Severe 0/14/12
Endoscopic severity




Corticosteroids and 5-ASA 3
Corticosteroids, 5-asa and azathioprine 5
Corticosteroids and azathioprine 1
5-ASA and azathioprine 3
Response to therapy 21
Reactivation (after/before 6 months) 6 (1/5)
Rescued by anti-TNF-α 6
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was detected in samples incubated with isotype antibody.
Epithelial ST2 expression was absent in all responder and
non-responder patients analyzed.
Discussion
In this prospective study of UC patients with active
disease, we consecutively measured sST2 levels during a
1-year follow-up and compared those with FC, the ca-
nonically defined biomarker of activity in IBD patients
[23–25]. Our results demonstrate for first time that
sST2 is an easily detectable marker of UC evolution
and effectiveness of therapy.
Several studies reporting the association of the IL-33/
ST2 signalling pathway with IBD pathogenesis in pa-
tients and animal models have attempted to address the
actual contribution of each component of the pathway
[26, 27]. In this context, the sST2 variant, acting as a
decoy receptor for IL-33, is increased in UC [10, 15].
Fig. 2 Distribution of serum ST2 according to response to therapy. a Serum ST2 levels during the follow-up period were determined in each
patient and are shown as one symbol in the scatter plot. Horizontal lines indicate medians and whiskers (interquartile ranges). Differences were
assessed using Kruskal-Wallis test (*** p < 0.0001). b Serum ST2 levels at baseline and 6 months in responders (R) and non-responders
(NR) in relation to therapy decreased only in responders. Differences were assessed using Wilcoxon signed rank test (*** p < 0.0001). c FC
levels in the 1-year follow-up and (d) at baseline and 6 months in R and NR in relation to therapy decreased in both subgroups. Panel E
shows the correlation between serum ST2 levels and Mayo clinical subscore, Mayo endoscopic subscore, and total ST2 intestinal mucosa
content, with a trend line for each correlation. Discontinuous line indicates cut-off value. Rs: Spearman’s rank correlation coefficient
Fig. 3 Correlation of ST2 and fecal calprotectin levels in patients. Serum ST2 and FC levels were determined at baseline, 1, 3, 6 and 12 months of
follow-up. Total ST2 intestinal was measure at baseline and 6 months. Correlation between serum (a) and total intestinal ST2 (b) according to FC
levels were assessed. Each symbol in the scatter plot represents the measurement in individual patients, with a trend line for this association. Rs:
Spearman’s rank correlation coefficient (p < 0.05)
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We proposed ST2 as a potential activity biomarker, with
a cut-off value of 74.87 pg/mL, that might allow dis-
tinction between active and inactive disease with
83 % sensitivity and specificity [15]. At this cut-off
value, we found a lower specificity (44 vs 83 %), sug-
gestive of a poorer discrimination of the group of
inactive patients or those with sST2 levels <74.87 pg/
mL. The higher sST2 levels at baseline and from
unresponsive patients/reactivations (endoscopic score ≥ 2)
in the vast majority of all detections might explain the
lower specificity.
sST2 has also been considered a biomarker of diseases
that affect different tissues undergoing deep inflamma-
tory reactions and necrosis; a cut-off of 150 pg/mL and
5.8 ng/mL was determined to predict sudden cardiac
death in patients with chronic heart failure and left
Fig. 4 Distribution of serum ST2 and fecal calprotectin in patients rescued with biological therapy. Serum sST2 (a) and fecal calprotectin (b) levels
are shown for patients non-responsive to conventional therapy or with reactivation but rescued with biological therapy. Each symbol in the scatter plot
represents the measurement in individual patients; horizontal lines indicate medians and whiskers (the interquartile ranges). Differences were assessed
using Kruskal-Wallis test with Dunn’s multiple comparison post-test (*p < 0.05 and **p < 0.01)
Fig. 5 Immunolocalization of ST2 in colonic tissue from responder and non-responder patients during baseline and 6-month follow-up. a Total
ST2 immunoreactivity was restricted to the cellular infiltrate in the lamina propria at 6 months in responder patients (right), while in patients
showing reactivation, total ST2 was increased in inflamed mucosa, also confined to the cellular infiltrate (left); baseline examination revealed
extensive immune cell infiltration of the intestinal mucosa and damaged tissue with loss of architecture. b Total ST2 immunoreactivity at
6 months expressed as arbitrary units (A.U.) and normalized to baseline levels in responders and non-responders (n = 4 in each group) was
higher in the non-responders. Hoechst 33342/ ST2 (blue/green) (60X)
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ventricular systolic dysfunction, as well as in patients
with rheumatoid arthritis, respectively [28, 29].
In our follow-up study, patients in biological remission
showed normalization of sST2, with values close to the
cut-off previously determined [15], suggesting that low
sST2 levels predict improvement in the inflammatory
state. Moreover, we find that increased sST2 levels in
UC patients with active disease directly correlate with
higher expression of total ST2 in intestinal mucosa, in-
cluding sST2 and ST2L, consistent with previous obser-
vations [15] and suggesting that the increased total ST2
immunoreactivity in non-responder patients is mostly at
the expense of newly produced sST2 by cells infiltrating
the mucosa. In responder patients, we found no conclu-
sive evidence of a decrease in total ST2 immunoreactiv-
ity, possibly reflecting the inability of the technique used
to distinguish between the two protein isoforms and its
limitation in assessing protein quantity. Moreover, in re-
sponder patients, ST2+ cells infiltrating the mucosa
might be less effective than those present in non-
responders, although additional cell markers are needed
to support this hypothesis. The components of this in-
flammatory microenvironment, including TNF-α, IL-33
and IL-1β produced by infiltrating and resident cells
(neutrophils, mast cells and fibroblasts) have been
shown to upregulate sST2 expression in vitro [30], al-
though the current lack of a differential tool to detect
ST2 variants limits the interpretation of tissue immuno-
detection of total ST2. On the other hand, studies of in-
testinal inflammation in murine models have reported
that IL-33 itself can play a beneficial or harmful role in
IBD depending on the induction of mucosal damage
(acute or chronic) or the colitogenic used, arguing
against a precise role of the IL-33/ST2 axis. Indeed, IL-
33 serum levels did not correlate with the activity score
in UC patients [15] and in the present cohort, we found
no association between IL33 serum levels with therapy
response.
The difficulty in evaluating disease activity in UC
patients using clinical, endoscopic and histological ap-
proaches has led to greater interest in identifying new
biochemical markers that directly reflect intestinal in-
flammation. Recently, the usefulness of FC as a bio-
marker has been explained by the fact that inflammation
causes neutrophil activation, resulting in a proportional
release-to-damage ratio. Yamamoto et al. [31] showed
that consecutive measurements of FC in UC patients
with proctitis were able to monitor relapse during main-
tenance therapy with mesalazine suppositories. A cut-off
value of 55 μg/g was used to assign those patients who
maintained clinical remission, although the optimal
cut-off for defining activity in IBD remains controver-
sial [32, 33]. Indeed, FC cut-off values ranging from
50 to 250 μg/g have been used [23, 34] that differ
depending on the test used [35, 36]. In our study, we
used quantitative ELISA and defined a cut-off of
99.26 μg/g with an AUC of 0.87 to distinguish indi-
viduals with an inactive endoscopic score (0–1) from
those with activity indices (2–3) [37]. The cut-off
value obtained for our cohort is similar to that previ-
ously described [38].
In 7 of 8 reactivations in non-responders from our co-
hort, FC levels showed a decrease despite detectable
endoscopic inflammation, although FC values were
above the cut-off defined in the current analysis. Unex-
pectedly, FC did not correlate with the endoscopic score,
possibly related to the treatment received or presence of
liquid stool [39]. Moreover, an inverse association be-
tween FC and neutrophil infiltration has been reported
in patients under remission, with high protein levels in
stool [40]. Finally, daily fluctuations of up to 40 % have
been described for FC determined in four independent
stool samples from active patients [41], suggesting that a
single FC detection in active patients is not sufficient for
a therapeutic decision.
In contrast, the increased inflammatory state of the
mucosa in 5 of 8 reactivations of non-responders simul-
taneous with augmented sST2 levels indicates that this
protein can predict lack of response to the therapy used.
The direct association between endoscopic score and
sST2 might reflect an inflammatory process related to
mucosal damage, while the production and secretion of
FC requires massive infiltration of neutrophils into the
lamina propria [42, 43]. While no test can replace colon-
oscopy with biopsy to determine the inflammatory condi-
tion of the intestinal mucosa, the ability of sST2 levels to
predict inflammatory status identifies the need to incorp-
orate analysis of sST2 in selecting patients who require
control for reactivation through colonoscopy.
sST2 levels have been also identified as a biomarker in
heart failure, efficiently assessing cardiac remodelling
and fibrosis; sST2 has been shown to efficiently monitor
the effectiveness of an optimized treatment in chronic
heart failure patients [44], with increased levels that may
be a good predictor of cardiac decompensation as well
as worsening renal function.
To date, there are few reports on the behavior of sST2
according to the medication used in IBD patients. We
found some association of sST2 with the use of systemic
steroids [15], and others have reported the effect of
infliximab on this molecule [10]. However, no study has
demonstrated how ST2 levels fluctuate in serial and con-
tinuous follow-up in relation to endoscopic index.
Based on our previous finding [15], we recruited
patients who at baseline had a moderate or severe endo-
scopic index (≥2) in any analyzed section of the colon.
During the follow-up, serial ST2 measurements decreased
in those patients with a reduced endoscopic index at
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6 months, indicating a positive response to therapy. In
those patients, FC levels were also significantly decreased
in direct correlation to sST2 levels. Further association
studies between sST2 and FC in a larger cohort of UC pa-
tients are needed, as well as such analyses in CD and in
IBD pediatric patients. Correlation studies between sST2,
histologic scores and disease risk might also provide
additional information about the strength of this bio-
marker as has been demonstrated with FC [45].
Our analyses of a one-bounded cohort of UC patients
during a 1-year follow-up revealed a direct correlation
between sST2 levels and inflammatory activity, strongly
suggesting that sST2 is a reliable biomarker of active
UC. It will be interesting to examine the predictive role
of sST2 for reactivation risk in a cohort of inactive pa-
tients or undergoing clinical and endoscopic remission
(Mayo subscore 0) and identifying serum levels of this
biomarker in a follow-up every 4 months, a protocol in
which FC was shown to predict disease recurrence [31].
Finally, it will be interesting to monitor both the behav-
ior of sST2 in a cohort of severe UC patients and the
relevance of elevated sST2 content in predicting colec-
tomy risk in a 1-year follow-up, as shown for FC [46].
Conclusions
The accuracy of sST2 in endoscopic detection of UC
strongly suggests its usefulness in monitoring relapse
and outcome, as well as in identifying patients likely to
benefit from a particular treatment.
Additional file
Additional file 1: Figure S1. Distribution of serum IL33 according to
response to therapy. Serum IL33 levels at baseline and 6 months in
responders (R) and non-responders (NR) in relation to therapy without
significant differences (p > 0.05). Differences were assessed using Wilcoxon
signed rank test. (TIFF 25551 kb)
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